All Relations between working memory and lamina i of gray matter of spinal cord

Reference Sentence Publish Date Extraction Date Species
Aung Tun, Arushi Khurana, Raphael Mwangi, Brian K Link, Yucai Wang, Andrew Feldman, Carrie A Thompson, Anne J Novak, Jose Caetano Villasboas, Gita Thanarajasingam, Umar Farooq, Sergei I Syrbu, Grzegorz S Nowakowski, Thomas E Witzig, Stephen M Ansell, Lisa M Rimsza, James R Cerhan, Thomas M Habermann, Matthew J Maure. Causes of Death in Low Grade B-Cell Lymphomas in the Rituximab Era: A Prospective Cohort Study. Blood advances vol issue 2022 35849723 the incidence of lymphoma related deaths varied by subtype, ranging from 3.7% at 10 years in extranodal marginal zone lymphoma (emzl) to 19.3% in lymphoplasmacytic lymphoma (lpl)/waldenstr\xc3\xb6m macroglobulinemia (wm). 2022-07-18 2022-07-25 Not clear
Aruna Rangan, Erica Reinig, Ellen D McPhail, Karen L Rec. Immunohistochemistry for LEF1 and SOX11 Adds Diagnostic Specificity in Small B-Cell Lymphomas. Human pathology vol issue 2022 35066013 immunohistochemistry (ihc) was performed for lef1 and sox11 on 354 sbcls (129 cll/ sll, 33 mcl, 142 marginal zone lymphomas (mzl): nodal mzl (nmzl)-40, extranodal mzl (enmzl)-28, splenic mzl (smzl)-74 cases and 50 lymphoplasmacytic lymphomas/ waldenstrom macroglobulinemias (lpl/ wm). 2022-01-23 2022-01-27 Not clear
Karima Amaador, Josephine M I Vos, Steven T Pals, Willem Kraan, Johan A Dobber, Monique C Minnema, Harry R Koene, Peter C de Bruin, Aiko H Zwinderman, Marie Jos\\xc3\\xa9 Kerste. Discriminating between Waldenstr\\xc3\\xb6m macroglobulinemia and marginal zone lymphoma using logistic LASSO regression. Leukemia & lymphoma vol issue 2021 34961399 discrimination between waldenstr\xc3\xb6m macroglobulinemia (wm) and marginal zone lymphoma (mzl) of the bone marrow (bm) can be difficult due to overlap in clinical, histopathologic, and immunophenotypic characteristics. 2021-12-28 2022-01-13 Not clear
Lori A Lesli. Novel Therapies for Follicular Lymphoma and Other Indolent Non-Hodgkin Lymphomas. Current treatment options in oncology vol 22 issue 12 2021 34694508 when selecting therapy for patients with indolent non-hodgkin lymphoma (inhl) including follicular (fl), marginal zone (mzl), small lymphocytic (sll), and lymphoplasmacytic lymphoma (lpl)/waldenstr\xc3\xb6m macroglobulinemia (wm), there are several factors to consider. 2021-12-01 2022-01-13 Not clear
Sung-Nan Pei, Ming-Chung Wang, Ming-Chun Ma, Ching-Yuan Kuo, Chun-Kai Liao, Hong Qiu, Lee Anne Rothwell, Yanfang Li. A comprehensive retrospective cohort study of the journey of B-cell lymphoma in Taiwan. Scientific reports vol 11 issue 1 2021 33980914 this retrospective cohort study used electronic medical records from a regional medical centre in southern taiwan to follow-up 441 patients newly diagnosed with common b-nhl subtypes: diffuse large b-cell lymphoma (dlbcl), follicular lymphoma (fl), chronic lymphocytic leukaemia/small lymphocytic lymphoma (cll/sll), marginal zone lymphoma (mzl), mantle cell lymphoma (mcl), and waldenstr\xc3\xb6m macroglobulinemia (wm), between 01-jan-2008 and 31-dec-2013, until 31-dec-2017. 2021-11-01 2022-01-13 Not clear
Raja Shekhar, Shano Naseem, Jogeshwar Binota, Neelam Varma, Pankaj Malhotr. Frequency of MYD88 L256P mutation and its correlation with clinico-hematological profile in mature B-cell neoplasm. Hematology/oncology and stem cell therapy vol 14 issue 3 2021 33217360 b-cell neoplasms are clonal tumors of b cells at various stages of maturation, including diffuse large b-cell lymphoma (dlbcl), chronic lymphocytic lymphoma (cll), burkitt lymphoma (bl), lymphoplasmacytic lymphoma (lpl)/waldenstr\xc3\xb6m's macroglobulinemia (wm), splenic marginal zone lymphoma (smzl), nodal marginal zone lymphoma (nmzl), mantle cell lymphoma (mcl), follicular lymphoma (fl), and hairy cell leukemia (hcl). 2021-09-16 2022-01-13 Not clear
Mesut G\\xc3\\xb6\\xc3\\xa7er, Erdal Kurto\\xc4\\x9fl. Safety and efficacy analysis of ibrutinib in 32 patients with CLL and various B-cell lymphomas: real-world data from a single-center study in Turkey. Blood research vol 55 issue 4 2021 33303706 here, we demonstrate the efficacy and safety of ibrutinib using real-life data from patients with marginal zone lymphoma (mzl), diffuse large b-cell lymphoma (dlbcl), waldenstr?m macroglobulinemia (wm), and follicular lymphoma (fl), especially in chronic lymphocytic leukemia (cll) and mantle cell lymphoma (mcl). 2021-01-14 2022-01-13 Not clear
P\\xc4\\xb1nar C\\xc3\\xb6mert, Abdulkerim Y\\xc4\\xb1ld\\xc4\\xb1z, Murat Y\\xc4\\xb1ld\\xc4\\xb1r\\xc4\\xb1m, Hacer Berna Afacan \\xc3\\x96zt\\xc3\\xbcrk, \\xc3\\x87i\\xc4\\x9fdem Pala, Murat Albayrak, Meltem Ayl\\xc4\\xb. Prognostic Factors in Patients with Low-Grade Nonhodgkin Lymphoma. Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion vol 36 issue 1 2021 32158088 low-grade nonhodgkin lymphoma (lg-nhl) is characterized by indolent clinical course, which consist of marginal zone lymphoma (mzl), follicular lymphoma (fl), chronic lymphocytic leukemia/small lymphocytic lymphoma, lymphoplasmacytic lymphoma, waldenstrom macroglobulinemia (wm) as the most common subtypes. 2021-01-01 2022-01-13 Not clear
D Kazmierski, M L Palomba, C Barsigia. Utility of MYD88 in the Differential Diagnosis and Choice of Second-Line Therapy in a Case of Nonsecretory Lymphoplasmacytic Lymphoma versus Free Light Chain Waldenstrom's Macroglobulinemia. Case reports in hematology vol 2017 issue 2020 28286680 we present a case illustrating the utility of myd88 status in distinguishing atypical forms of wm from marginal zone lymphoma (mzl) and in selecting second-line therapy with ibrutinib. 2020-09-29 2022-01-13 Not clear
Wei Wang, Pei Li. Lymphoplasmacytic lymphoma and Waldenstr\\xc3\\xb6m macroglobulinaemia: clinicopathological features and differential diagnosis. Pathology vol 52 issue 1 2020 31767130 in addition, the differential diagnosis of lpl and wm from other mature b cell neoplasms is highlighted with a focus on distinction from marginal zone lymphoma and plasma cell neoplasms. 2020-07-29 2022-01-13 Not clear
Marzia Varettoni, Silvia Zibellini, Emanuela Boveri, Catherine Klersy, Chiara Candido, Sara Rattotti, Virginia V Ferretti, Irene Defrancesco, Silvia Mangiacavalli, Maria E Nizzoli, Elena Flospergher, Caterina Zerbi, Fabio Bergamini, Pietro Benvenuti, Marco Brociner, Gabriele Merati, Marco Paulli, Luca Arcain. A risk-stratification model based on the initial concentration of the serum monoclonal protein and MYD88 mutation status identifies a subset of patients with IgM monoclonal gammopathy of undetermined significance at high risk of progression to Waldenstr\\xc3\\xb6m macroglobulinaemia or other lymphoproliferative disorders. British journal of haematology vol 187 issue 4 2020 31276195 with a median follow-up of 83\xc2\xa0months (1214 person-years), 15 patients (8\xc2\xb75%) progressed to wm (n\xc2\xa0=\xc2\xa014) or marginal zone lymphoma (n\xc2\xa0=\xc2\xa01). 2020-07-08 2022-01-13 Not clear
Anna Raimbault, Sigrid Machherndl-Spandl, Rapha\\xc3\\xabl Itzykson, Sylvain Clauser, Nicolas Chapuis, St\\xc3\\xa9phanie Mathis, Jeroen Lauf, Anne-Sophie Alary, Barbara Burroni, Olivier Kosmider, Michaela Fontenay, Marie C B\\xc3\\xa9n\\xc3\\xa9, Fran\\xc3\\xa7oise Durrieu, Peter Bettelheim, Val\\xc3\\xa9rie Barde. CD13 expression in B cell malignancies is a hallmark of plasmacytic differentiation. British journal of haematology vol 184 issue 4 2019 30198568 the diagnosis of waldenstr\xc3\xb6m macroglobulinaemia (wm)/lymphoplasmacytic lymphoma (lpl) remains one of exclusion because other b-cell lymphoproliferative disorders (b-lpd), such as marginal zone lymphoma (mzl), can fulfil similar criteria, including myd88 l265p mutation. 2019-12-27 2022-01-13 Not clear
Saurabh Chhabra, Sandeep Jain, Amanda Fowler, Valeriy Sedov, Amarendra K Neppalli, Cynthia A Schandl, John Lazarchic. IgM Myeloma with Plasma Cell Leukemia: Case Report and Literature Review. Annals of clinical and laboratory science vol 47 issue 5 2018 29066491 it should be distinguished from malignant neoplasms of b cells with plasmacytic differentiation such as waldenstrom macroglobulinemia (wm) and marginal zone lymphoma with plasmacytic differentiation. 2018-01-26 2022-01-13 Not clear
Xin-Xin Cao, Qi Meng, Hao Cai, Tian-Hua He, Cong-Li Zhang, Wei Su, Jian Sun, Yue Li, Wei Xu, Dao-Bin Zhou, Jian L. Detection of MYD88 L265P and WHIM-like CXCR4 mutation in patients with IgM monoclonal gammopathy related disease. Annals of hematology vol 96 issue 6 2017 28280994 we identified the myd88 l265p somatic variant in cases with wm (39/42), mgus (8/18), nhl (14/41, including 4/13 diffuse large b cell lymphoma (dlbcl), 1/8 mucosa-associated lymphoid tissue, 3/6 splenic marginal zone lymphoma (smzl), 1/4 chronic lymphocytic leukemia, 2/3 nodal marginal zone lymphoma (nmzl), 1/2 mantle cell lymphoma, 1 burkitt lymphoma, and 1 b cell nhl that could not be classified), primary al (2/2), and igm-pn (1/1). 2017-08-15 2022-01-13 Not clear
Tomoyuki Sakai, Yasufumi Masaki, Nozomi Otsuki, Ippei Sakamaki, Shinji Kishi, Takayoshi Miyazono, Yoshimasa Urasaki, Jun Murakami, Tomomi Satoh, Takuji Nakamura, Haruka Iwao, Akio Nakajima, Takafumi Kawanami, Miyuki Miki, Yoshimasa Fujita, Masao Tanaka, Toshihiro Fukushima, Toshiro Okazaki, Takanori Ued. Prospective clinical study of R-CMD therapy for indolent B cell lymphoma and mantle cell lymphoma from the Hokuriku Hematology Oncology Study Group. Medical oncology (Northwood, London, England) vol 32 issue 9 2016 26275804 these patients' illnesses were fl (n\xc2\xa0=\xc2\xa021), nodal marginal zone b cell lymphoma (nmzb, n\xc2\xa0=\xc2\xa03), mcl (n\xc2\xa0=\xc2\xa03), splenic marginal zone b cell lymphoma (n\xc2\xa0=\xc2\xa02), hairy cell leukemia (n\xc2\xa0=\xc2\xa01), waldenstrom macroglobulinemia (wm, n\xc2\xa0=\xc2\xa01), and lymphoplasmacytic lymphoma (lpl, n\xc2\xa0=\xc2\xa02). 2016-12-13 2022-01-12 Not clear
Lian Xu, Zachary R Hunter, Nicholas Tsakmaklis, Yang Cao, Guang Yang, Jie Chen, Xia Liu, Sandra Kanan, Jorge J Castillo, Yu-Tzu Tai, James L Zehnder, Jennifer R Brown, Ruben D Carrasco, Ranjana Advani, Jean M Sabile, Kimon Argyropoulos, M Lia Palomba, Enrica Morra, Alessandra Trojani, Antonino Greco, Alessandra Tedeschi, Marzia Varettoni, Luca Arcaini, Nikhil M Munshi, Kenneth C Anderson, Steven P Treo. Clonal architecture of CXCR4 WHIM-like mutations in Waldenstr\\xc3\\xb6m Macroglobulinaemia. British journal of haematology vol 172 issue 5 2016 26659815 by combined as-pcr and sanger sequencing, cxcr4(whim) mutations were identified in 44/102 (43%), 21/62 (34%), 2/12 (17%) and 1/20 (5%) untreated wm, previously treated wm, igm mgus and marginal zone lymphoma patients, respectively, but no chronic lymphocytic leukaemia, multiple myeloma, non-igm mgus patients or healthy donors. 2016-07-06 2022-01-12 Not clear
Siegfried Jan. Waldenstr\\xc3\\xb6m macroglobulinemia: clinical and immunological aspects, natural history, cell of origin, and emerging mouse models. ISRN hematology vol 2013 issue 2014 24106612 this not only provides an intriguing link to new findings that natural effector igm(+)igd(+) memory b-cells are dependent on myd88 signaling, but also supports the hypothesis that wm derives from primitive, innate-like b-cells, such as marginal zone and b1 b-cells. 2014-06-24 2022-01-12 Not clear
Esteban Braggio, Rafael Fonsec. Genomic abnormalities of Waldenstr\\xc3\\xb6m macroglobulinemia and related low-grade B-cell lymphomas. Clinical lymphoma, myeloma & leukemia vol 13 issue 2 2013 23477936 to better characterize the genetic basis of wm, we performed a comparative genomic analysis with the related entities, lymphoplasmacytic lymphomas without monoclonal immunoglobulin m protein, marginal zone lymphomas, chronic lymphocytic leukemia, and monoclonal gammopathy of undetermined significance. 2013-12-10 2022-01-12 Not clear
C Jim\\xc3\\xa9nez, E Sebasti\\xc3\\xa1n, M C Chill\\xc3\\xb3n, P Giraldo, J Mariano Hern\\xc3\\xa1ndez, F Escalante, T J Gonz\\xc3\\xa1lez-L\\xc3\\xb3pez, C Aguilera, A G de Coca, I Murillo, M Alcoceba, A Balanzategui, M E Sarasquete, R Corral, L A Mar\\xc3\\xadn, B Paiva, E M Ocio, N C Guti\\xc3\\xa9rrez, M Gonz\\xc3\\xa1lez, J F San Miguel, R Garc\\xc3\\xada-San. MYD88 L265P is a marker highly characteristic of, but not restricted to, Waldenstr\\xc3\\xb6m's macroglobulinemia. Leukemia vol 27 issue 8 2013 23446312 no mutation was seen in normal donors, while it was present in 101/117 (86%) wm patients, 27/31 (87%) igm monoclonal gammapathies of uncertain significance (mgus), 3/14 (21%) splenic marginal zone lymphomas and 9/48 (19%) non-germinal center (gc) diffuse large b-cell lymphomas (dlbcls). 2013-10-21 2022-01-12 Not clear
Irene M Ghobria. Are you sure this is Waldenstrom macroglobulinemia? Hematology. American Society of Hematology. Education Program vol 2012 issue 2013 23233639 the differential diagnosis of wm includes igm-multiple myeloma, marginal zone lymphoma, mantle cell lymphoma, and follicular lymphoma. 2013-06-27 2022-01-12 Not clear
Page: 
1   2